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Abstract
Neuropsychiatric symptoms of Alzheimer’s disease (AD) such as depression may be asso-
ciated with pain, which according to the literature may be inadequately recognized and man-
aged in this population. This study aimed to identify the factors associated with analgesic
use in persons with AD; in particular, how AD severity, functional status, neuropsychiatric
symptoms of AD, co-morbidities and somatic symptoms are associated with analgesic use.
236 community-dwelling persons with very mild or mild AD at baseline, and their caregivers,
were interviewed over five years as part of the prospective ALSOVA study. Generalized Es-
timating Equations (GEEs) were used to estimate unadjusted and adjusted odds ratios
(ORs) for the factors associated with analgesic use over a five year follow-up. The propor-
tion of persons with AD using any analgesic was low (13.6%) at baseline and remained rela-
tively constant during the follow-up (15.3% at Year 5). Over time, the most prevalent
analgesic changed from non-steroidal anti-inflammatories (8.1% of persons with AD at Year
1) to acetaminophen (11.1% at Year 5). Depressive symptoms (measured by the Beck De-
pression Inventory, BDI) were independently associated with analgesic use, after effects of
age, gender, education, AD severity, comorbidities and somatic symptoms were taken into
account. For every one unit increase in BDI, the odds of analgesic use increased by 4%
(OR = 1.04, 95% confidence interval CI = 1.02-1.07). Caregiver depressive symptoms were
not statistically significantly associated with analgesic use of the person with AD. Depres-
sive symptoms were significantly associated with analgesic use during the five year follow-
up period. Possible explanations warranting investigation are that persons with AD may ex-
press depressive symptoms as painful somatic complaints, or untreated pain may cause
PLOS ONE | DOI:10.1371/journal.pone.0117926 February 17, 2015 1/1 8
a11111
OPEN ACCESS
Citation: Gilmartin JF-M, Väätäinen S, Törmälehto S,
Bell JS, Lönnroos E, Salo L, et al. (2015) Depressive
Symptoms Are Associated with Analgesic Use in
People with Alzheimer’s Disease: Kuopio ALSOVA
Study. PLoS ONE 10(2): e0117926. doi:10.1371/
journal.pone.0117926
Received: May 28, 2014
Accepted: January 4, 2015
Published: February 17, 2015
Copyright: © 2015 Gilmartin et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data is available upon
request due to ethical restrictions (it contains
personal information which may identify study
participants; this restriction is stated in the ethical
committee permission). Requests to access the data
can be made to the National Institute for Health and
Welfare Finland office. The Principal Investigator
(Anne Koivisto) has access to all data and can
request permission for another researcher to access
the data if necessary. ALSOVA Study Group leader
and Principal Investigator: Anne Koivisto MD, PhD,
Adjunct Professor, Senior Neurologist Consultant
Neurology, Institute of Clinical Medicine, University of
Eastern Finland, Neuroogy of Neuro Center, Kuopiodepressive symptoms. Greater awareness of the association between depressive symp-
toms and analgesic use may lead to safer and more effective prescribing for
these conditions.
Introduction
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration, impaired cogni-
tion, function, and behavioral and social skills. Neuropsychiatric symptoms of AD, such as apa-
thy, depression, irritability and agitation [1], can cause strain to the individual, their caregiver
and the healthcare system [2]. Improving quality of life (QoL) is one of the main aims of AD
management, which includes treating the symptoms of AD and any concurrent conditions [3].
As persons with AD are often older individuals with multiple co-morbidities, pain relief should
be one of the mainstays of therapy [4]. The literature has shown that standardized, stepwise an-
algesic treatment protocols can improve agitation, aggression and pain in persons with moder-
ate to severe dementia, and have the potential to reduce antipsychotic use [5].
Pain appears to be inadequately recognized and treated in persons with varying stages of
AD (including mild AD) and other dementias [4, 6–11]. Although many studies have shown
that persons with AD and other dementias use fewer analgesics than those without dementia
[6–10], the reverse phenomenon has also been shown [12, 13].[7] Nygaard et al (2005) identi-
fied that a lower proportion of older Norwegian care home residents with a dementia diagnosis
received analgesics ‘when required’ (12%) compared to those who were cognitively impaired
and did not have a dementia diagnosis (27%), or those without cognitive impairment (33%)
[10]. Similarly, Morrison et al (2000) reported that persons with advanced dementia who frac-
tured their hip, received one-third of the mean daily dose of opioid analgesia postoperatively
compared to those without cognitive impairment [4]. This is despite the fact that persons with
dementia are likely to experience pain to a similar extent as those without dementia [4, 11].
Despite these findings, there is a paucity of published literature exploring analgesic use in
persons with AD. Gallini et al (2013) outlined that persistent analgesic use in persons with
mild to moderate AD has not been examined in the published literature [9], despite the impor-
tance of involving these individuals in research. These individuals are often not under nursing
home care, their persistent pain may worsen AD progression, and AD progression may influ-
ence the experience of pain and subsequent need for analgesics [9]. Prevalence of acute analge-
sic use (use at any study visit) was found to be 25.6% (152/595) and persistent use (use on at
least two consecutive study visits, six months apart) was 13.1% (78/595) [9]. The most common
analgesic used alone or in combination was acetaminophen [9]. Females and individuals with
osteoarthritis were more likely to use analgesics persistently and statistically significant associa-
tions between persistent analgesic use, AD duration and recent change in Mini Mental State
Examination (MMSE) were identified [9]. While analgesic use may not be the focus of the fol-
lowing studies [14, 15], literature exploring other treatment regimens in persons with mild to
moderate AD can still give an indication of analgesic use in this population. In a study examin-
ing the effects of obstructive sleep apnoea treatment on cognitive function, 67.3% (35/52) of in-
dividuals were stable on analgesics [14], while in a study evaluating donepezil against placebo it
was found that analgesics were used by 32.0% of 2376 participants [15]. The published litera-
ture exploring pain perception in persons with mild to moderate AD can also inform this topic
[16, 17]. Jensen-Dahm et al (2014) examined pain tolerance in persons with mild to moderate
AD and identified that they exhibited a lower mechanical pain tolerance compared to controls
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and materials.[17]. It was also postulated that the reduced verbal report of pain may be a function of impaired
communication or memory problems associated with AD [17]. Cole et al (2006) identified that
the perception of pain was not diminished in persons with mild to moderate AD and postulat-
ed that this pain perception may differ when compared to persons with more advanced stages
of AD [16]. These findings support the theory that patterns of analgesic use may differ between
those with AD and those without, and among the different stages of AD severity.
There are also limitations associated with the current literature assessing analgesic use in
persons with AD. Data concerning both the person with AD and their caregiver are often not
collected [4, 8, 9], most studies are cross-sectional rather than longitudinal [7, 10, 11], and
medication utilization studies using administrative pharmacy information have not analyzed
rich clinical data [6].
The present study aimed to examine the factors associated with analgesic use in persons
with AD. In particular, how AD severity, functional status, neuropsychiatric symptoms of AD
(e.g. behavioral and depressive symptoms), co-morbidities and somatic symptoms are associat-
ed with analgesic use. The purpose of this study was to further understand how analgesics are
used in persons with AD.
Methods
Data source and study sample
This study utilized data collected as part of the ALSOVA study, a prospective, five year, rehabil-
itation study, conducted by the Department of Neurology, University of Eastern Finland
[3, 18]. The primary aim of the ALSOVA study was to evaluate whether an early psychosocial
rehabilitation intervention, combining education and support for persons with very mild (Clin-
ical dementia rating, CDR 0.5) or mild (CDR 1) AD and their caregivers, could postpone insti-
tutionalization of the person with AD. The ALSOVA study intervention comprised intensive
psychosocial courses conducted during the first two years after AD diagnosis. These courses in-
volved: evaluation of the current family situation, lectures about AD, increasing awareness of
available social services and methods for caregivers to cope with stress, and social activities for
the caregiver and person with AD [19]. One of the secondary ALSOVA study aims was to gen-
erate new knowledge to improve the care of persons with AD, this included describing
medication utilization. The ALSOVA study design and sample have been previously described
[3, 18, 20].
In the ALSOVA study, persons with AD and their caregivers were recruited from April
2002 to September 2006 from hospital memory polyclinics in three hospital districts of Eastern
and Central Finland, during the first year after AD diagnosis [3]. To be eligible for inclusion in
the study, persons with AD had to have very mild or mild AD [3]. They had to provide in-
formed consent, live in the community, be free of comorbidities that could affect cognition at
baseline, and have a family caregiver (spouse, sibling, child) who they were preferably in daily
contact with [3, 20].
A geriatrician or neurologist diagnosed AD using the criteria devised by the National Insti-
tute of Neurological and Communicative Disorders and Stroke and AD and Related Disorders
Association (NINCDS-ADRDA), and the Diagnostic and Statistical manual of Mental Disor-
ders (DSM-IV) [3, 20]. To diagnose AD, the NINCDS-ADRDA recommend obtaining infor-
mation from the individual’s medical history, neuropsychological tests, laboratory studies and
neurologic, psychiatric and clinical examinations [21]. Probable AD can be diagnosed if there
is insidious onset of cognitive deterioration, in the absence of other systemic or brain diseases
that could account for progressive memory and other cognitive deficits [21]. Possible AD may
be diagnosed in the presence of other comorbidities if AD is considered the more likely cause
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firmation [21]. The DSM-IV considers the individual’s family history, evidence of decline in
memory and learning and cognition, the absence of comorbidities that are likely to be contrib-
uting to the cognitive decline, and the presence of AD genetic mutations [22]. In this study, a
diagnosis of very mild AD (prodromal) was confirmed by the study neurologist, using criteria
proposed by Dubois et al (2007) [23]. All persons with AD also underwent comprehensive di-
agnostic evaluation and brain imaging [3]. The mean time between AD diagnosis and partici-
pants’ baseline visit was an average of five months [20].
After the persons with AD and their caregivers were recruited, they were followed-up annu-
ally for five consecutive years (i.e. data were collected from 2002 to 2011). Each annual study
visit included a neuropsychological test battery conducted by a psychologist, and a structured
interview between the study nurse, the caregiver and the person with AD [3]. During these vis-
its, socio-demographic details (age, gender, years of education) and general health (comorbidi-
ties and medication use) were collected [3].
In this study, the longitudinal data were used to examine factors associated with analgesic
use in persons with AD. Although this was not the primary aim of the ALSOVA study, the rig-
orous medication assessment made the secondary analyzes of analgesic use possible. Published
studies that have examined medication use data collected as part of other, larger studies, sup-
ports the rationale of this study [3, 9, 18, 20]. The study sample comprised 236 patient-caregiv-
er dyads and up to five years of follow-up data, resulting in a total of 806 person observations
(data points). Data from the fourth study visit were omitted from the present analyzes as they
were collected using a postal survey, instead of structured interviews.
Medication assessment and analgesic use
At each study visit interview, caregivers were asked to report all medications (including pre-
scription, non-prescription, complementary and alternative medications) used by the person
with AD. Alternative medications particularly referred to non-prescription ‘natural’, herbal or
mineral products, such as gingko biloba. Information collected on structured forms included
medication start and end dates, regularity of use, and whether medications were ‘still in use’.
Medications ‘still in use’ included those that were regularly used during the study, for example,
daily or monthly. Medications were categorized using the Anatomical Therapeutic Chemical
(ATC) Classification System recommended by the World Health Organization (WHO) [24].
Analgesics were defined as non-steroidal anti-inflammatories (NSAIDs, ATC code: M01A),
opioids (N02A), and acetaminophen and high dose acetylsalicylic acid (N02B). Low-dose ace-
tylsalicylic acid, glucosamine and anti-migraine medications were not classified as analgesics.
Analgesic use was dichotomized as ‘using analgesics’ or ‘not using analgesics’. In this study, the
person with AD was defined as using analgesics at each study visit if they were reported to have
analgesic medications ‘still in use’ at the time of the study visit, including medications used in
single doses, on an ‘as-needed basis’, or regularly.
Factors associated with analgesic use (parameters to explore)
Factors potentially associated with analgesic use were first identified by their clinical relevance
[25, 26]. The hypothesis outlining what factors may be associated with analgesic use was de-
fined before conducting analyzes. It was hypothesized that AD severity (evaluated using the
CDR scale) [27], functional status (evaluated using the AD Cooperative Study Activity of Daily
Living inventory, ADCS-ADL) [28], neuropsychiatric symptoms of AD (e.g. behavioral symp-
toms evaluated using the Neuropsychiatric inventory, NPI [29] and depressive symptoms eval-
uated using the Beck Depression Inventory, BDI) [30]), co-morbidities and somatic symptoms
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tionnaire) [31] were associated with analgesic use. Although this study only included persons
with very mild or mild AD at baseline, AD severity was still considered a potential factor asso-
ciated with analgesic use, as the severity of AD in the study population increased over the study
follow-up period.
Tools and instruments
The severity of AD was evaluated using the CDR scale [27] and its Sum of Boxes (CDR-SOB)
applicant [32]. The CDR is a widely used and validated instrument used to measure the severity
and progression of dementia. The CDR scale includes six domains, with scores in each domain
combined to obtain a composite score (no dementia = 0, very mild = 0.5, mild = 1, moderate =
2, and severe dementia = 3) and a sum of boxes score [18] ranging from 0 to 18 [32]. The terms
very mild (CDR 0.5) and mild AD (CDR 1) were used in the ALSOVA study to describe the dif-
ferent stages of AD at baseline. Those with CDR 0.5 had amnestic mild cognitive impairment
and other biomarkers that supported the diagnosis of AD, as described by criteria proposed by
Dubois et al (2007) [23]. O’Bryant et al (2008) identified that CDR-SOB scores compare well
with CDR scores used for dementia staging [32]. A CDR score of 0.5 corresponds to a CDR-
SOB score of 0.5–4.0 (indicating questionable impairment to very mild dementia) [32]. A CDR
score of 1 corresponds to a CDR-SOB score of 4.5–9.0 (indicating mild dementia) [32]. Addi-
tionally, the MMSE scores can be used as a surrogate measure for the CDR and can therefore be
mapped to correspond to CDR scores, where MMSE 30 = CDR 0, MMSE 26 to 29 = CDR 0.5,
MMSE 21 to 25 = CDR 1, MMSE 11 to 20 = CDR 2, and MMSE 0 to 10 = CDR 3 [33].
The existence and degree of behavioral symptoms was evaluated using the 12-item Neuro-
psychiatric inventory (NPI), which identifies caregiver-reported behavioral and psychological
problems during the one month prior to the study visit interview [29]. Depressive symptoms
and depression were assessed using the validated, self-administered 21-item Beck Depression
Inventory (BDI) [30], which has been used to assess persons with dementia [34] and AD [35].
Although BDI is a self-reported tool used to evaluate depression, it captures the subjective ex-
perience of depression and gives an indication of clinical depression, with scores from 0–9 indi-
cating no depression, 10–18 mild depression, 19–29 moderate depression, and 30–63 severe
depression [36]. The persons with AD were not diagnosed with clinical depression in
this study.
As the ALSOVA study did not use a validated instrument to rate pain, somatic symptoms
(symptoms of discomfort) were evaluated for their association with analgesic use, and assessed
with one screening question ‘discomfort and symptoms’ from the 15D self-administered, vali-
dated, health-related QoL questionnaire [31]. Symptoms such as pain, aches, nausea and itch
are included in this item [31]. In its entirety the 15D instrument comprises 15 dimensions:
breathing, mental function, speech, vision, mobility, usual activities, vitality, hearing, eating,
elimination, sleeping, distress, discomfort and symptoms, sexual activity and depression [31].
Each dimension is divided into five grades of severity [31]. The five grades of severity associat-
ed with the ‘discomfort and symptoms’ dimension includes: no, mild, marked, severe, and un-
bearable physical discomfort or symptoms. For this study, marked, severe and unbearable
grades were combined into ‘moderate to unbearable discomfort or symptoms’. The 15D can
also be used as a preference-based health-related QoL measure when the dimensions are
weighted using population-based preferences to obtain a single index score, leading to a final
score of between 0 (dead) and 1 (no problems on any dimension) [31]. However, the prefer-
ence-weighted measures were not within the scope of this study.
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son with AD [28]. All comorbidities, other than rheumatoid arthritis or severe arthrosis, had
similar, statistically non-significant associations with the odds of using analgesics. For this rea-
son they were combined into a single summary score, ‘number of other comorbidities’.
Statistical procedures and analyzes
The data were described using means, ranges, proportions and measures of variance (standard
errors (SE) of the mean). The association between potential factors and analgesic use were ex-
amined by estimating their impact on the odds of the person with AD using analgesics. This
was accomplished by using Generalized Estimating Equations (GEEs) to estimate the unadjust-
ed and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for associations between
independent variables (factors) and analgesic use (dependent variable) [37].
GEEs used in this study can be considered as repeated measures logistic regression, as they
are an extension of generalized linear models, specified with a logit link function and binomial
distribution function. However, the key difference to conventional logistic regression is that
GEEs account for the dependent nature of data points, seen in longitudinal study designs
where the observations obtained from each study participant are typically correlated with each
other [38, 39]. Previously, GEEs have been used in published longitudinal studies examining
factors associated with an increased risk of dementia in persons with congestive heart failure
[40], the association between digital literacy and decreased cognitive decline in older adulthood
[41], and the temporal relationship between depressive symptoms, function, and cognitive sta-
tus in persons with AD [42]. In this study, GEEs were employed specifically to address the de-
pendent, correlated nature of observations, as each study participant was examined (observed)
repeatedly, up to five times i.e. in total, 1 to 5 observations per individual during the study. As
GEEs include all study participants in analyzes, rather than only those who remained in the
study, participant attrition is also accounted for and an advantage is gained over conventional
binary logistic regression. In the GEEs used in this study, variance (i.e. SE and 95% CIs) was es-
timated using semi-robust estimation.
Initially, GEEs were used to estimate the unadjusted ORs in the bivariate analyzes, to exam-
ine which of the clinically relevant potential factors (described above) also had the potential to
be statistically significantly associated with analgesic use. Multivariate models were then creat-
ed by including all clinically relevant and potentially statistically significant (p<0.2 in bivariate
analyzes) factors into the models as independent variables. In the multivariate models, these in-
dependent variables are considered to predict the dependent variable (analgesic use). In addi-
tion, age, gender and education were included in the model as factors potentially affecting
analgesic use. The ORs resulting from these multivariate models are referred to as adjusted
ORs, as they represent the effect of an independent variable on the odds of an individual using
an analgesic, when the effects of the other independent variables included in the model have
been accounted for.
All statistical analyzes were performed using Intercooled Stata version 9 (StataCorp. 2005.
Stata Statistical Software: Release 9. College Station, TX: StataCorp LP). The conventional
threshold of p <0.05 was used as criteria for rejecting the null hypothesis.
Ethics statement
The ethics committee of Kuopio University Hospital, the Finnish Supervisory Authority for
Welfare and Health, and the Finnish Ministry of Social Affairs and Health approved the
ALSOVA project. A consent form was signed by both the caregiver and the person with AD.
The caregiver also provided proxy consent on behalf of the person with AD.
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Participants
Baseline characteristics of all 236 participants and their caregivers are presented in Table 1.
The study sample of persons with AD comprised an almost even proportion of females
(51.3%) and males, who were mostly older (mean age 75.7 years). The majority of persons with
AD were either not likely to be suffering from depression (BDI score 0–9, 50.0%) or were po-
tentially suffering from mild depression (BDI score 10–18, 38.6%) and either reported no
(51.7%) or mild symptoms of discomfort (39.8%). Caregivers of persons with AD were mostly
Table 1. Characteristics of persons with AD and their caregivers at baseline.
Person with AD n = 236
Female gender, n (%) 121 (51.3)
Age, mean years (range) 75.7 (53.8–90.3)
Education, mean years (range) 7.6 (1.0–20.0)
Depressive symptoms (BDI), mean (range) 10.5 (0–38)
0–9, n (%) 118 (50.0)
10–18, n (%) 91 (38.6)
19–63, n (%) 27 (11.4)
Severity of AD (CDR-SOB), mean (range) 4.1 (1–8)
Global CDR score, n (%)
0.5 128 (54.2)
1.0 108 (45.8)
2.0 0 (0.0)
3.0 0 (0.0)
Functional status (ADCS-ADL), mean (range) 64.6 (33–78)
Behavioral symptoms (NPI), mean (range) 8.9 (0–50)
Rheumatoid arthritis or severe arthrosis, n (%) 77 (32.6)
Number of other comorbidities, mean (range) 1.7 (0–6)
15D—discomfort and symptom item, n (%)
None 122 (51.7)
Mild 94 (39.8)
Moderate to unbearable 20 (8.5)
Caregiver n = 236
Female gender, n (%) 157 (66.5)
Age, mean years (range) 66.2 (35.6–84.4)
Education, mean years (range) 9.3 (4–21)
Relationship to person with AD, n (%)
Spouse 166 (70.3)
Child 55 (23.3)
Other 15 (6.4)
Depressive symptoms (BDI), mean (range) 9.3 (0–32)
0–9, n (%) 131 (55.5)
10–18, n (%) 83 (35.2)
19–63, n (%) 22 (9.3)
AD = Alzheimer’s disease; BDI = Beck Depression Inventory; CDR = Clinical Dementia Rating; SOB =
Sum of boxes.
doi:10.1371/journal.pone.0117926.t001
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and were either not likely to be suffering from depression (55.5%) or were potentially suffering
from mild depression (35.2%). The behavioral disturbances which persons with AD exhibited
included apathy, depression, irritability and agitation [3].
The proportion of persons with AD who used analgesics was low at baseline (n = 32, 13.6%
of all persons with AD) and remained relatively constant over the follow-up period (n = 11,
15.3% at Year 5). At baseline, the majority of persons with AD who were using analgesics, were
using NSAIDs (n = 19, 8.1%), while acetaminophen alone became the most prevalent analgesic
used at Year 5 (n = 8, 11.1%). Over the same time period, the most commonly used medica-
tions per category were ibuprofen (NSAID), acetaminophen (other analgesics and antipyret-
ics), and codeine in combination with acetaminophen (opioids), closely followed by tramadol
(opioids). Eight hundred and six observations of any analgesic use were collected over the five
years, resulting in 109 observations of analgesic use (Table 2).
Table 3 describes the characteristics of persons with AD who used analgesics at different fol-
low-up points. Over the five year follow-up, the proportion of persons reporting no depressive
symptoms increased compared with other BDI categories (34.3% to 62.5%), the severity of AD
measured by CDR increased (moderate AD 0% to 36.4%, and severe AD 0% to 27.3%), and
functional status decreased (mean ADCS-ADL 63.3 to 36.9). Behavioral symptoms measured
by mean NPI increased in severity (9.9 to 18.2) and the proportion of persons reporting arthrit-
ic conditions decreased (62.5% to 45.5%). Reporting of mild discomfort increased compared
with other categories of discomfort (46.9% to 71.4%).
Among caregivers of persons with AD who used analgesics, the proportion of caregivers
who had depressive symptoms over the five year follow-up increased from 43.8% (n = 14) to
63.6% (n = 7). Over the follow-up, increases were seen in those likely to have mild depression
(37.5%, n = 12 at Year 1 and 45.5%, n = 5 at Year 5), and moderate or severe depression (6.3%,
n = 2 at Year 1 and 18.2%, n = 2 at Year 5), based on BDI scores.
As illustrated in Table 4, AD severity (CDR-SOB), antidepressant use, or caregiver depres-
sive symptoms (measured by BDI), were not significantly associated with analgesic use in the
multivariate analyzes (p>0.1). Depressive symptoms (p = 0.002) and rheumatoid arthritis or
severe arthrosis (p = 0.006) were the only factors statistically significantly associated with anal-
gesic use, if symptoms of discomfort were not included in the model (Table 4, Model A). Both
depressive symptoms and arthritic conditions were also still significantly associated with anal-
gesic use after symptoms of discomfort were included as an independent variable (Table 4,
Model B), even though symptoms of discomfort themselves were significantly associated with
analgesic use (Model B, p<0.007). Additionally, when using ADCS-ADL instead of CDR-SOB
in the multivariate models (ADCS-ADL and CDR-SOB are highly correlated with each other),
similar statistically significant findings for the association between depressive symptoms and
analgesic use are produced. The association between ADCS-ADL and analgesic use was not sta-
tistically significant. Additionally, no significant association between behavioral symptoms
Table 2. Types of analgesics used by persons with Alzheimer’s disease, n (%).
Baseline (n = 236) Year 1 (n = 198) Year 2 (n = 168) Year 3 (n = 131) Year 5 (n = 73)
Any analgesic use 32 (13.6) 21 (10.6) 23 (13.7) 22 (16.8) 11 (15.3)
NSAIDs (M01A) 19 (8.1) 8 (4.0) 13 (7.7) 4 (3.1) 3 (4.2)
Analgesic (N02) 16 (6.8) 13 (6.6) 13 (7.8) 19 (14.5) 9 (12.3)
Other analgesics and antipyretics (N02B) 13 (5.5) 11 (5.6) 9 (5.4) 17 (13.0) 8 (11.1)
Opioids (N02A) 3 (1.3) 3 (1.5) 5 (3.0) 3 (2.3) 1 (1.4)
doi:10.1371/journal.pone.0117926.t002
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cluded in the multivariate models.
This means that depressive symptoms are independently associated with analgesic use re-
gardless of any other variable included in the models presented in Table 4.
As only a small proportion of persons with AD could be classified as potentially having se-
vere depression in the study sample based on their BDI scores, sensitivity analyzes were con-
ducted with GEEs to exclude these potential outliers (Table 5). When persons with AD who
reported severe depressive symptoms (defined as BDI > 29, n = 13) were removed from the
multivariate GEE model, the strength of association between depressive symptoms and analge-
sic use increased. At any data collection point over the follow-up period, only one person with
AD who used analgesics had severe depression. Depressive symptoms (p = 0.001) and rheuma-
toid arthritis or severe arthrosis (p = 0.017) were the only factors statistically significantly asso-
ciated with analgesic use, if symptoms of discomfort were not included in the model (Table 5,
Model A). Both depressive symptoms and arthritic conditions were also still significantly asso-
ciated with analgesic use after symptoms of discomfort were included as an independent vari-
able (Table 5, Model B), even though symptoms of discomfort themselves were significantly
associated with analgesic use (Model B, p = 0.001).
Depending on the statistical model, the OR for depressive symptoms was between 1.03 and
1.06, that is, for every one unit increase in BDI, the odds of analgesic use increases by approxi-
mately 3% to 6%.
Table 3. Characteristics of persons with AD who used analgesics over the ﬁve year follow-up.
Baseline (n = 32) Year 1 (n = 21) Year 2 (n = 23) Year 3 (n = 22) Year 5 (n = 11)
Female gender, n (%) 23 (71.9) 13 (61.9) 13 (56.5) 12 (54.5) 7 (63.6)
Age, mean years (range) 75.7 (63.2–86.6) 79.5 (70.1–91.3) 79.4 (65.3–87.4) 83.3 (72.4–90.4) 81.0 (68.2–87.6)
Education, mean years (range) 6.8 (1–14) 7.3 (4–14) 6.7 (1–11) 6.2 (1–11) 6.5 (6–10)
Depressive symptoms (BDI), mean (SE) 13.8 (1.4) 12.3 (1.4) 14.1 (1.8) 11.6 (1.8) 9.9 (2.6)
0–9, n (%) 11 (34.3) 9 (42.9) 9 (40.9) 11 (55.0) 5 (62.5)
10–18, n (%) 13(40.6) 9 (42.9) 7 (31.8) 4 (20.0) 2 (25.0)
19–29, n (%) 7 (21.9) 3 (14.3) 5 (22.7) 4 (20.0) 1 (12.5)
30–63, n (%) 1 (3.1) 0 (0.0) 1 (4.5) 1 (5.0) 0 (0.0)
Severity of AD (CDR-SOB), mean (SE) 4.3 (0.3) 6.2 (0.6) 6.9 (0.6) 9.3 (0.8) 10.7 (1.3)
Global CDR score, n (%)
0.5 16 (50.0) 2 (9.5) 4 (17.4) 1 (4.5) 1 (9.1)
1.0 16 (50.0) 16 (76.2) 12 (52.2) 10 (45.5) 3 (27.3)
2.0 0 (0.0) 3 (14.3) 6 (26.1) 9 (40.9) 4 (36.4)
3.0 0 (0.0) 0 (0.0) 1 (4.3) 2 (9.1) 3 (27.3)
Functional status (ADCS-ADL), mean (SE) 63.3 (1.7) 56.4 (2.9) 48.4 (3.7) 37.4 (4.6) 36.9 (6.5)
Behavioral symptoms (NPI), mean (SE) 9.9 (1.6) 13.0 (2.8) 12.4 (1.8) 15.4 (3.1) 18.2 (7.1)
Rheumatoid arthritis or severe arthrosis, n (%) 20 (62.5) 10 (47.6) 13 (56.5) 12 (54.5) 5 (45.5)
Number of other comorbidities, mean (SE) 1.9 (0.2) 2.2 (0.2) 2.1 (0.2) 2 (0.2) 1.8 (0.5)
15D—discomfort and symptom item, n (%)
None 11 (34.4) 5 (23.8) 7 (31.8) 7 (35.0) 2 (28.6)
Mild 15 (46.9) 10 (47.6) 12 (54.5) 8 (40.0) 5 (71.4)
Moderate to unbearable 6 (18.8) 6 (28.6) 3 (13.6) 5 (25.0) 0 (0.0)
AD = Alzheimer’s disease; BDI = Beck Depression Inventory; SE = standard error; CDR = Clinical Dementia Rating; SOB = Sum of boxes; ADCS = AD
Cooperative Study; ADL = activities of daily living; NPI = Neuropsychiatric Inventory.
doi:10.1371/journal.pone.0117926.t003
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time (all persons with AD).
Factor All persons with AD
Model A, n = 784 Model B, n = 783
OR 95% CI p OR 95% CI p
Depressive symptoms (BDI) 1.04 1.02–1.07 0.002 1.03 1.00–1.06 0.028
Follow-up visit 1.05 0.86–1.29 0.636 0.99 0.81–1.22 0.926
Age, years 1.05 1.00–1.10 0.052 1.05 1.00–1.10 0.035
Female gender 1.54 0.88–2.68 0.131 1.64 0.94–2.87 0.081
Education, years 0.94 0.85–1.04 0.205 0.94 0.85–1.04 0.222
Rheumatoid arthritis or severe arthrosis 2.13 1.24–3.66 0.006 2.13 1.26–3.59 0.005
Number of other comorbidities 1.12 0.91–1.37 0.278 1.15 0.96–1.39 0.137
Severity of AD (CDR-SOB) 0.97 0.88–1.06 0.509 0.98 0.90–1.08 0.749
15D—discomfort and symptom item (vs. none)
Mild 1.45 0.91–2.29 0.116
Moderate to unbearable 2.73 1.33–5.60 0.006
GEEs with logit link, binomial distribution function and unstructured correlation matrix.
P-value for statistical signiﬁcance: p<0.05. n represents number of observations included in the model, both individuals who use analgesics and who
do not.
AD = Alzheimer’s disease; BDI = Beck Depression Inventory; CDR = Clinical Dementia Rating; SOB = Sum of boxes; GEE = Generalized Estimating
Equations
doi:10.1371/journal.pone.0117926.t004
Table 5. Generalized Estimating Equation models (multivariate analyzes) exploring the impact of ﬁve year patient factors on analgesic use over
time (persons with AD and non-severe depression, BDI<30).
Factor Persons with AD and non-severe depression (BDI<30)
Model A, n = 771 Model B, n = 770
OR 95% CI p OR 95% CI p
Depressive symptoms (BDI) 1.06 1.02–1.09 0.001 1.04 1.01–1.08 0.018
Follow-up visit 1.08 0.88–1.32 0.480 1.01 0.82–1.24 0.929
Age, years 1.04 0.99–1.09 0.089 1.05 1.00–1.10 0.054
Female gender 1.59 0.90–2.81 0.113 1.73 0.97–3.08 0.063
Education, years 0.94 0.84–1.04 0.196 0.94 0.84–1.04 0.212
Rheumatoid arthritis or severe arthrosis 1.97 1.13–3.44 0.017 1.99 1.15–3.43 0.014
Number of other comorbidities 1.15 0.94–1.39 0.167 1.19 0.99–1.43 0.071
Severity of AD (CDR-SOB) 0.97 0.88–1.06 0.485 0.98 0.89–1.08 0.751
15D—discomfort and symptom item (vs. none)
Mild 1.42 0.91–2.21 0.126
Moderate to unbearable 3.11 1.55–6.27 0.001
GEEs with logit link, binomial distribution function and unstructured correlation matrix.
P-value for statistical signiﬁcance: p<0.05. n represents number of observations included in the model, both individuals who use analgesics and who
do not.
AD = Alzheimer’s disease; BDI = Beck Depression Inventory; CDR = Clinical Dementia Rating; SOB = Sum of boxes; GEE = Generalized Estimating
Equations.
doi:10.1371/journal.pone.0117926.t005
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of analgesic use (Model A), as well as how symptoms of discomfort affect this relationship
(Model B). The rapid increase in the probability of analgesic use as depressive symptoms wors-
en is apparent even after the data are adjusted for age, gender, education, AD severity and co-
morbidities. Although symptoms of discomfort were significantly correlated with depressive
symptoms (Spearman’s rho = 0.316, p<0.001), no significant interaction between symptoms of
discomfort and depressive symptoms was observed in the multivariate GEE models.
Fig 1. Adjusted probability of analgesic use in relation to depressive symptoms and level of discomfort (means and CIs) in persons with AD. Data
is presented for persons with AD. Probability was estimated using GEEs with logit link function, binomial distribution and unstructured correlation matrix. Data
is adjusted for age, gender, follow-up visit, years of education, CDR-SOB and comorbidities (arthritic conditions and number of other comorbidities). A BDI
score 30 was considered to be indicative of severe depression. n represents number of observations included in the model, both individuals who use
analgesics and who do not.
doi:10.1371/journal.pone.0117926.g001
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The present study examined the factors associated with analgesic use in persons with AD, in
particular, how AD severity, functional status, neuropsychiatric symptoms of AD (e.g. behav-
ioral and depressive symptoms), comorbidities and somatic symptoms affect the probability of
the person with AD using analgesics. The main finding of this study was that depressive symp-
toms were independently associated with analgesic use over a five year follow-up of persons
with early stage AD at baseline. Furthermore, a significant association was not observed be-
tween AD severity, functional status or behavioral symptoms and analgesic use. Although the
relationship between pain and depression in persons with dementia has been partly explored
in earlier cross-sectional studies [43, 44], there is a paucity of literature exploring the associa-
tion of analgesic use and depression in AD [6–10]. To the best of our knowledge, this study is
the first to report this association and therefore contributes to the growing body of literature
concerning analgesic medication management in AD.
There are several potential explanations for the main study finding. Firstly, it is possible that
depression and pain were sufficiently coexistent among the study sample to explain the associa-
tion. The study sample may have been experiencing pain that warranted analgesic use.The asso-
ciation between pain and depression in persons with dementia has been documented [43–45].
Arthritis is also highly prevalent in older Finns [46] and is associated with analgesic use [9]. This
study identified that arthritis was significantly associated with analgesic use (p<0.02, OR = 1.97–
2.13), along with symptoms of discomfort (p<0.007, OR = 2.73–3.11). Furthermore, a significant
correlation between symptoms of discomfort and depressive symptoms was observed. However,
although pain could not be evaluated in the study sample, the data showed a significant associa-
tion between depressive symptoms and analgesic use evenafter the effect of significant comor-
bidities (e.g. arthritis and severe arthrosis) and symptoms of discomfort had been adjusted for.
Another possible explanation for the main finding of this study may be that persons with
AD use somatic complaints, such as headache or stomach ache, to express depressive symp-
toms, which in turn leads to analgesic use. Although further research is needed to support this
theory, this claim is partially supported by the study conducted by Engedal et al (2011), where
it was speculated that ‘multiple physical complaints’ was an unspecific mood symptom express-
ed by depressed persons with AD [47]. After interviewing 112 persons with AD it was identi-
fied that those diagnosed with depression were significantly more likely to present with
‘multiple physical complaints’ than those not diagnosed with depression (p = 0.001) [47]. Even
after adjusting for impairment in ADLs and the number of physical disorders, ‘multiple physi-
cal complaints’ was significantly associated with depression [47].
It can be suggested that there is the potential for analgesics to be used unnecessarily in per-
sons with AD, if analgesics are treating somatic complaints of depressive symptoms. Further
research is needed to confirm this. If this explanation were true, it could lead to polypharmacy
[48, 49] and inadequately treated depression. In persons with AD, depression can lead to worse
QoL, greater disability in ADL, faster cognitive decline, relatively higher mortality, and a higher
frequency of caregiver depression and burden [50–52]. Symptoms of depression occur com-
monly in persons with AD, but their prevalence can decrease over time [42]. Of persons diag-
nosed with probable AD in a North American study, Holtzer et al (2005) described a 40%
baseline prevalence of depressive symptoms, decreasing to 24% after five years of follow-up
[42]. Andreasen et al (2013) identified a 12.4% prevalence of depression in 1612 older persons
with dementia from eight different countries [53]. Analgesics, such as opioids, are also associat-
ed with adverse drug events including respiratory depression, nausea and vomiting, gastroin-
testinal reflux and constipation [54], which could in turn lead to increased utilization of health
care services.
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tient depression [50], this study did not show any significant relationship between caregiver de-
pression and analgesic use in persons with AD. At each study visit interview, caregivers were
asked to report all medications used by the person with AD. It is possible that interview data
used in the current study may not have sufficiently captured the use of over-the-counter anal-
gesics, which caregivers may have more control over. Caregivers may have been more likely to
report prescription medications, however, they were instructed to report all medications, and
there was no evidence of any systematic underreporting of over-the-counter medications.
Low analgesic use in individuals with dementia [6–10], and no significant change in persis-
tent analgesic use over time [9] has also been identified in the literature. Participants in this
study were recruited in the early stages of AD and may not have been experiencing advanced
stages of painful comorbidities, which may be more likely to accompany more advanced age
and stages of AD, potentially explaining their low overall analgesic use. Participant drop-out
may also be an alternative explanation as persons who used more analgesics may have left the
study. The most common reasons for participant drop-out included institutionalization (34/
236), health deterioration (15/236) or death (20/236). A significant difference in the baseline
severity of AD compared to participants who continued through the follow-up was not ob-
served (p = 0.155). Additionally, systematic or major differences between individuals who
dropped-out or remained in the study were not observed. Similar drop-out rates have been ob-
served in other studies involving persons with AD [55]. It has been suggested in the literature
that low analgesic use in persons with AD and other dementias may be explained by their diffi-
culty in communicating pain, recollecting painful episodes, or requesting analgesics [4]. Addi-
tionally, the concern for analgesic adverse drug events [4, 7] and its influence on prescribing
patterns, may explain the finding that acetaminophen was the most commonly used analgesic
as AD progressed [9, 10], as opposed to NSAIDs.
Strengths and limitations
Firstly, it is a strength that data analyzed in this study were derived from interviews rather than
administrative pharmacy data or prescription registries. Although interviews rely on the accu-
racy of patient and caregiver self-reports, they provide an opportunity to capture rich clinical
data and determine which medications are in current use. However, analgesic doses used were
not investigated. Secondly, despite the absence of a statistically significant relationship between
caregiver depression and analgesic use, this study provided a unique comparison of linked pa-
tient and caregiver data. Thirdly, the repeated and longitudinal process of data collection pro-
vided a novel examination of analgesic use over a five year follow-up, compared to studies
assessing only cross-sectional data. Lastly, the use of GEEs takes advantage of the longitudinal
data by including all participants in analyzes, rather than only those remaining in the study at
each time point of data collection.
It is a potential limitation that data were collected in only three Finnish hospital districts.
For this reason it is not clear to what extent the findings are generalizable to other regions or
countries. However, the patterns of analgesic use identified in this study, are similar to those
identified in studies conducted in other countries [6–10]. Secondly, although an AD-specific
pain scale was not used, ‘discomfort and symptoms’ was assessed using one part of a validated
QoL instrument (15D). Thirdly, medication use between each yearly study visit interview may
not have been adequately captured. Fourthly, any relationship between the depressive compo-
nent of the NPI and analgesic use was not examined in this study. Fifthly, only a few persons
with AD potentially had severe depression, however additional analyzes were conducted where
these individuals were omitted and an even stronger association between depressive symptoms
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and effect relationship between depressive symptoms and analgesic use in persons with AD in
this study, because data concerning when analgesics were first commenced and when depres-
sive symptoms were first reported were not analyzed. However, an association between depres-
sive symptoms and analgesic use in this study sample was found.
Future directions
Relative to the number of studies assessing diagnosis and treatment of depression [56], there is
limited published research investigating the ways in which persons with AD express their de-
pressive symptoms [47]. This study highlights the importance of considering the different pre-
sentations of depression in this setting [57], and the need for further research in persons with
AD. More research and quality improvement programs regarding pain assessment and man-
agement in dementia are also needed [10, 11, 58].
This study enables greater understanding of how analgesics are used in persons with AD
and highlights that pain management is an area that warrants further consideration upon initi-
ation and review of overall AD treatment plans. Further research is needed to explore the asso-
ciation between depressive symptoms and analgesic use and identify whether depressive
symptoms lead to greater analgesic use, or whether pain, and consequently analgesic use, leads
to greater reporting of depressive symptoms.
Conclusion
Depressive symptoms in persons with AD were significantly associated with analgesic use dur-
ing the five year follow-up period. Possible explanations that warrant further investigation is
that persons with AD may express depressive symptoms as painful somatic complaints, leading
to analgesic use, or inadequately treated pain may cause depressive symptoms. Greater aware-
ness of the association between depressive symptoms and analgesic use may lead to safer and
more effective prescribing for these conditions in early stage AD and ultimately improved
QoL.
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